Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Small Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Small Pharma şirketinin toplam hissedar öz sermayesi CA$8.0M ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$12.9M ve CA$4.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$7.68m
Eşitlik	CA$8.05m
Toplam yükümlülükler	CA$4.88m
Toplam varlıklar	CA$12.92m

Son finansal sağlık güncellemeleri

Recent updates

We're A Little Worried About Small Pharma's (CVE:DMT) Cash Burn Rate

Aug 26

Can Small Pharma (CVE:DMT) Afford To Invest In Growth?

Feb 13

Here's Why We're Watching Small Pharma's (CVE:DMT) Cash Burn Situation

Oct 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DMT 'nin kısa vadeli varlıkları ( CA$12.4M ) kısa vadeli yükümlülüklerini ( CA$4.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: DMT şirketinin kısa vadeli varlıkları ( CA$12.4M ) uzun vadeli yükümlülüklerini ( CA$154.3K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DMT borçsuzdur.

Borcun Azaltılması: DMT un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DMT şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: DMT un, serbest nakit akışı her yıl % 47.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Small Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Small Pharma Inc. Common Stock to Be Deleted from OTC Equity

Small Pharma to Be Delisted from the TSXV and Removed from OTCQB Venture Market, Upon Completion of Arrangement

Small Pharma to Be Delisted from the TSXV and Removed from OTCQB Venture Market, Upon Completion of Arrangement

We're A Little Worried About Small Pharma's (CVE:DMT) Cash Burn Rate

Can Small Pharma (CVE:DMT) Afford To Invest In Growth?

Here's Why We're Watching Small Pharma's (CVE:DMT) Cash Burn Situation

Recent updates

Small Pharma Inc. Common Stock to Be Deleted from OTC Equity

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

Small Pharma to Be Delisted from the TSXV and Removed from OTCQB Venture Market, Upon Completion of Arrangement

Small Pharma to Be Delisted from the TSXV and Removed from OTCQB Venture Market, Upon Completion of Arrangement

Insider recently sold CA$284k worth of stock

Small Pharma Inc. Reports Positive Top-line Data from SPL026 (DMT-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Small Pharma Inc., Annual General Meeting, Oct 12, 2023

We're A Little Worried About Small Pharma's (CVE:DMT) Cash Burn Rate

Insider recently sold CA$101k worth of stock

Small Pharma Inc. Announces Management Changes

Small Pharma Inc. Confirms the First Subject Has Been Dosed in A Phase I Study Evaluating SPL028

Can Small Pharma (CVE:DMT) Afford To Invest In Growth?

Small Pharma Inc. Reports Positive Top-Line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Small Pharma Confirms First Patient Dose in its Phase I Study Exploring Intramuscular Administration of SPL026

Small Pharma Inc. Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Price target decreased to CA$1.42

High number of new and inexperienced directors

Small Pharma Inc. Receives Approval for First-In-Human Phase I Clinical Trial with SPL028

Here's Why We're Watching Small Pharma's (CVE:DMT) Cash Burn Situation

Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients with Major Depressive Disorder

Key Executive recently bought CA$61k worth of stock

Small Pharma Inc. Receives Approval for DMT-Assisted Psychotherapy and Ssri Drug Interaction Study

Small Pharma Inc. Announces CEO Changes, Effective from July 20, 2022

Small Pharma Inc., Annual General Meeting, Jul 19, 2022

Small Pharma Inc. Announces Appoints Alastair Riddell as Chief Operating Officer

Small Pharma Inc. Announces Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

Small Pharma Inc. Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy

Small Pharma Inc. Expands Phase I/IIa Clinical Trial With Additional Study Site

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin